Page 4 - நல்லிணக்கம் உயிர் அறிவியல் ஹோல்டிங்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer - Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial - News provided by Share this article Share this article EXTON, Pa., April 20, 2021 /PRNewswire/  Castle Creek Biosciences, Inc. (the Company ), a privately held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize disease-modifying therapies for patients suffering from orphan conditions for which there is a lack of available treatment options, today announced that Matthew Gantz has been appointed President and Chief Executive Officer. He will also serve as a member of the Company s Board of Directors. Mr. Gantz succeeds John Maslowski, who will continue to serve the company as Chief Operating Officer.

United statesMatthew gantzAdam daleyKaren caseyJeff aroninJohn maslowskiEmalex biosciencesCompany board of directorsPrinceton universityMarine corps scholarship foundationHarvard business schoolCastle creek biosciences incBerry company public relationsChiron corporationAcureon pharmaceuticals incAbbott laboratories